AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 142,902 shares, a decline of 56.5% from the January 29th total of 328,268 shares. Based on an average trading volume of 7,677,784 shares, the short-interest ratio is presently 0.0 days. Approximately 4.4% of the shares of the company are sold short. Approximately 4.4% of the shares of the company are sold short. Based on an average trading volume of 7,677,784 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

AIM ImmunoTech Trading Down 7.8%

AIM ImmunoTech stock traded down $0.08 during mid-day trading on Friday, hitting $0.91. The company’s stock had a trading volume of 98,733 shares, compared to its average volume of 2,076,344. AIM ImmunoTech has a 1 year low of $0.77 and a 1 year high of $36.00. The stock’s fifty day moving average is $1.19 and its two-hundred day moving average is $1.84. The firm has a market capitalization of $2.99 million, a PE ratio of -0.05 and a beta of 1.26.

Institutional Investors Weigh In On AIM ImmunoTech

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC acquired a new position in AIM ImmunoTech during the second quarter worth about $87,000. DRW Securities LLC increased its stake in shares of AIM ImmunoTech by 60.6% during the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after purchasing an additional 26,254 shares in the last quarter. Finally, Sabby Management LLC acquired a new position in shares of AIM ImmunoTech during the 3rd quarter worth approximately $79,000. 12.02% of the stock is currently owned by institutional investors and hedge funds.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.